What to Expect When Starting an Injectable GLP-1 or Dual GIP/GLP-1 Agonist for Obesity

What to Expect When Starting an Injectable GLP-1 or Dual GIP/GLP-1 Agonist for Obesity

U ntil the past decade or so, the most common treatments for obesity were diet, exercise, and oral weight loss drugs. But with the introduction of GLP‑1 and dual GIP/GLP-1 agonists, people with obesity now have a new tool to help manage the condition.

Obesity is a chronic disease, and we need to treat it like one,” says Sara Velayati, MD, an obesity medicine specialist at the Fleischer Institute Medical Weight Management Center at Montefiore Einstein in the Bronx, New York.

If lifestyle changes haven’t led to sufficient weight loss, your doctor may recommend using one of these medications in conjunction with healthy eating and regular exercise. The catch: It can take time and fine-tuning to find the right dose and manage side effects.

Here’s what to expect when starting a GLP-1 or dual GIP/GLP-1 agonist.

How to Prepare to Start a GLP-1 or Dual GIP/GLP-1 Agonist for Obesity

Checking in with your healthcare provider and tweaking your habits before you start treatment can help you stay healthy and lessen — or even prevent — side effects.

Treatment Steps

Most GLP-1 and dual GIP/GLP-1 agonists for obesity are given once a week via injection, which you can do yourself at home. Although you’ll prepare the injection spot the same way, the process differs a little for a prefilled injection pen versus a needle and syringe. Be sure to read the instructions for your particular medication.

Preparation

  • The injector pens or vials should be kept in the refrigerator (36 to 46 degrees F). Some medications can stay at room temperature, out of direct sunlight, for 21 to 28 days. Check your specific medication for storage instructions.
  • Take the pen or vial out of the fridge and let it sit on the counter for about 15 minutes. This helps take the chill out of the injection, which can make the process more comfortable. 
  • While you’re waiting, double-check that the medicine looks clear and the expiration date hasn’t passed.
  • Wash your hands thoroughly for at least 20 seconds.
  • Pick an injection spot, such as your belly (at least two inches away from the navel) or the front of your thigh. 
  • Wipe the skin with an alcohol swab and let it air-dry completely.

Injection With a Prefilled Pen

  • Pull off the cap and place the flat end of the pen firmly against your cleaned skin at a 90-degree angle.
  • Press down. You’ll hear a click or see a progress bar start moving. This means the medicine is being delivered.
  • After the click or once the bar stops moving, hold the pen in place and count to 10. This ensures all the medication enters your body, and there’s none left over in the pen.
  • Place the used pen into a designated sharps container or puncture-proof container, such as a laundry detergent bottle.

Injection With a Needle and Syringe

  • Remove the rubber cap from the vial of medication and clean the rubber stopper with an alcohol swab.
  • Remove the cap from the syringe.
  • If the needle is not already attached to the syringe, place the needle on the tip of the syringe and twist to the right until it’s firmly in place. Then, remove the needle cap. 
  • Hold the syringe with the needle pointing up, and pull down on the plunger until it draws in the same amount of air as the dose of medication you’re taking. 
  • Place the vial on a flat surface. Insert the needle through the rubber stopper on the vial, and push down on the plunger to inject the air into the vial.
  • Leaving the needle in the vial, turn the vial upside down. Ensure the tip of the needle is inserted in the liquid. 
  • Slowly pull down on the plunger and fill the syringe to the dose prescribed by your doctor. 
  • Remove the needle from the vial and insert it into the injection site. 
  • Slowly push down on the plunger to inject the medication. Leave the needle in your skin for at least five seconds to ensure you receive the full dose. 
  • Place the used syringe into a designated sharps container or puncture-proof container, such as a laundry detergent bottle.

What It’s Like to Take a GLP-1 or Dual GIP/GLP-1 Agonist

When taking a GLP-1 or dual GIP/GLP-1 agonist, you may experience:

Treatment Timeline

These medications mimic the body’s naturally occurring GLP-1 hormone, which is produced in the small intestine. There can be a bit of a Goldilocks effect, though: Too much GLP-1, and you’ll experience symptoms such as nausea and vomiting. Too little GLP-1, and you won’t get any weight loss benefits. That’s why, in the early stages of treatment, your doctor will gradually increase the dose to find a steady level that works for you.

Side Effects of GLP-1 and Dual GIP/GLP-1 Agonists

From constipation and nausea to fatigue and hair thinning, side effects can range from mildly inconvenient to completely intolerable. The good news? Most of them can usually be resolved with a few lifestyle and treatment tweaks.

 

Rare but Serious — Call Your Provider Promptly

  • Severe stomach pain, persistent vomiting, or an inability to eat
  • Gallbladder symptoms (fever, severe pain, yellowing of the eyes/skin)
  • Blurry vision or sudden vision loss

Real-Life Tips on Taking a GLP-1 or Dual GIP/GLP-1 Agonist

Know What’s Next on a GLP-1 or Dual GIP/GLP-1 Agonist

Managing obesity is much more than a matter of willpower. It often requires a treatment toolbox that combines a healthy diet and regular exercise with medication, such as a GLP-1 or dual GIP/GLP-1 agonist, to help you lose weight and take control of your health.

Work closely with your care team to ensure you’re on the right dose, find ways to get relief from side effects, and learn which lifestyle changes to implement to help maintain bone and muscle mass as you lose weight. The dose you take can be adjusted to ensure you stay healthy and feel good while working toward your weight loss goals.

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Additional Sources
  • WHO Guideline on the Use of Glucagon-Like Peptide-1 (GLP-1) Therapies for the Treatment of Obesity in Adults. World Health Organization. 2025.
  • Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults With Overweight or Obesity. The New England Journal of Medicine. September 18, 2025.
  • Wilding JPH et al. Once-Weekly Semaglutide in Adults With Overweight or Obesity. The New England Journal of Medicine. March 18, 2021.
  • Do D et al. GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes. JAMA Network Open. May 2024.
  • Tinsley GM et al. Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments. Journal of the Endocrine Society. November 2024.
  • West S et al. Weight Regain After Cessation of Medication for Weight Management: Systematic Review and Meta-Analysis. BMJ. January 7, 2026.
  • Medaris A. A New Era of Weight Loss: Mental Health Effects of GLP-1 Drugs. American Psychological Association. July/August 2025.
  • Reiss AB et al. Weight Reduction With GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules. March 13, 2025.
  • Caffrey MK. Liraglutide Approved Under New Name to Treat Obesity. American Journal of Managed Care. August 6, 2020.
  • Novo Nordisk Receives FDA Approval for Wegovy to Treat Adults With Obesity Based on Unprecedented Efficacy for a Prescription Medicine in Clinical Trials. Novo Nordisk. June 4, 2021.
  • FDA Approves New Medication for Chronic Weight Management. U.S. Food and Drug Administration. November 8, 2023.
  • Obesity Treatment Overview. Johns Hopkins Medicine.
  • Self-Injection Guide. Alberta Health Services. 2019.
  • Kapan A et al. Real-World Insights Into Incretin-Based Therapy: Associations Between Changes in Taste Perception and Appetite Regulation in Individuals With Obesity and Overweight: A Cross-Sectional Study. Diabetes, Obesity and Metabolism. September 2025.

Adam Gilden, MD, MSCE

Medical Reviewer

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight Management and Wellness Clinic in Aurora. Dr. Gilden works in a multidisciplinary academic center with other physicians, nurse practitioners, registered dietitians, and a psychologist, and collaborates closely with bariatric surgeons.

Gilden is very involved in education in obesity medicine, lecturing in one of the obesity medicine board review courses and serving as the lead author on the Annals of Internal Medicine article "In the Clinic" on obesity.

He lives in Denver, where he enjoys spending time with family, and playing tennis.

Susan Jara

Author

Susan Jara is a health communications strategist and writer with more than 15 years of experience transforming complex medical information into clear, accurate, and engaging content for diverse audiences of patients and caregivers. She specializes in patient education, health literacy, and SEO-driven content strategy, with expertise across chronic disease, mental health, addiction, arthritis, autoimmune conditions, and wellness.

Susan holds a bachelor’s degree in journalism and media studies from New York University’s Gallatin School of Individualized Study. Her career includes leadership roles at the Global Healthy Living Foundation and Health Monitor Network, where she developed multichannel health content across web, email, podcasts, video, social media, and print. Susan's work reaches millions of readers each year, and she collaborates with leading healthcare providers, researchers, advocacy groups, and industry partners to create resources that reach millions of readers each year.